NCT00003802View on ClinicalTrials.gov

Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

February 28, 1999

Study Completion Date

October 31, 2002

Conditions
Intraocular MelanomaMelanoma (Skin)
Interventions
DRUG

pyrazoloacridine

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00003802 - Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma | Biotech Hunter | Biotech Hunter